pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Rezurock
drug
save

belumosudil mesylate

Marketedupdated 6mo ago
by Kadmon Pharmaceuticals LLC
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • tagApproval20 co-mentions · 5 sources
  • drugREZUROCK20 co-mentions · 5 sources
  • tagSmall Molecule10 co-mentions · 5 sources

all catalysts(5)

approval · 5
Jul 16, 2021
approval
5y ago
REZUROCK (BELUMOSUDIL MESYLATE) — FDA approval
belumosudil mesylate
→
Nov 9, 2023
approval
3y ago
REZUROCK (BELUMOSUDIL MESYLATE) — FDA approval
belumosudil mesylate
→
Apr 10, 2024
approval
3y ago
REZUROCK (BELUMOSUDIL MESYLATE) — FDA approval
belumosudil mesylate
→
Dec 30, 2024
approval
2y ago
REZUROCK (BELUMOSUDIL MESYLATE) — FDA approval
belumosudil mesylate
→
Jan 15, 2026
approval
10mo ago
REZUROCK (BELUMOSUDIL MESYLATE) — FDA approval
belumosudil mesylate
→

Trials studying belumosudil mesylate

  • phase1A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female Subjectscompletedn=32
  • phase1A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjectscompletedn=8
  • phase1A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjectscompletedn=32

Patent cliff

source: FDA Orange Book
first barrier falls
Jul 16, 2028
~1.7 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (5)

  • Jul 14, 2042method-of-use (U-4014)US 12097202
  • Apr 9, 2035method-of-use (U-3369)US 11311541
  • Jun 20, 2034compositionUS 8357693
  • Oct 7, 2033method-of-use (U-3246)US 10183931
  • Oct 7, 2033method-of-use (U-3246)US 10696660

FDA exclusivities (2)

  • Jul 16, 2028ODE-362Orphan Drug (7y)1.7y
  • Jul 16, 2026NCENew Chemical Entity (5y)

News(1)

  • CinRx teams with Sam Waksal's Graviton on ROCK2 for PAH, other cardio conditions
    Sam Waksal is doubling down on ROCK2 after his first work on the target led to the chronic graft-versus-host disease medicine Rezurock. Now, the Graviton Bioscience CEO is teaming up with a cardio…
    endpoints · 17d ago
brand
Rezurock
generic
belumosudil mesylate
indication
Graft Versus Host Disease (GVHD)
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?